Table 1.
Baseline characteristics of patients with and without prior ARV use.
| Characteristic | Prior ARV use N = 122 | ARV naïve N = 2592 | P-value |
|---|---|---|---|
| Age (years) Median IQR | 34.7 (29.1–40.5) | 37.0 (32.0–43.3) | <0.001 |
| Sex, n (%) | |||
| Female | 29 (23.8) | 1108 (42.8) | <0.001 |
| Male | 93 (76.2) | 1484 (57.3) | |
| VL (log10) Median (IQR) | 4.9 (4.1–5.6) | 5.2 (4.4–5.6) | 0.240 |
| CD4 (Log10) Median (IQR) | 177 (147–202) | 133 (62–203) | 0.0017 |
| WHO clinical stage | 0.275 | ||
| I/II | 54 (44.3) | 1019 (39.3) | |
| III/IV | 68 (55.7) | 1573 (60.7) | |
| Type of initial NNRTI | |||
| EFV | 73 (59.8) | 1545 (59.6) | 0.964 |
| NVP | 49 (40.2) | 1046 (40.4) | |
| Type of initial NRTI backbone | |||
| TDF + XTC | 43 (35.3) | 866 (33.4) | 0.790 |
| d4T + 3TC | 29 (23.8) | 695 (26.8) | |
| ABC + 3TC | 2 (1.6) | 66 (2.6) | |
| ZDV + 3TC | 48 (39.3) | 964 (37.2) | |
| †ART adherence | 0.977 | ||
| ≥95% | 96 (86.5) | 2044 (86.4) | |
| <95% | 15 (13.5) | 322 (13.6) | |
Data are presented as n (%), unless stated otherwise.
3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; d4T, stavudine; EFV, efavirenz; NVP, nevirapine; TDF, tenofovir; VL: viral load; XTC, lamivudine or emtricitabine; ZDV, zidovudine.
†Mean adherence measured as 30-day self-reported adherence over 12 months.